Comparison of Two Mitotane Starting Dose Regimens in Patients With Advanced Adrenocortical Carcinoma
نویسندگان
چکیده
منابع مشابه
Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma.
OBJECTIVE Mitotane, a drug used to treat adrenocortical cancer (ACC), inhibits multiple enzymatic steps of adrenocortical steroid biosynthesis, potentially causing adrenal insufficiency. Recent studies in vitro have also documented a direct inhibitory effect of mitotane at the pituitary level. The present study was aimed to assess the hypothalamic-pituitary-adrenal axis in patients with ACC rec...
متن کاملClinical results of the use of mitotane for adrenocortical carcinoma.
Mitotane (o,p'-DDD) acts mainly as an inhibitor of intramitochondrial pregnenolone and cortisol synthesis. Its adrenolytic effect depends on metabolic activation due to conversion to o,p'-DDA and o,p'-DDE. The drug has been used for 40 years in the treatment of adrenocortical carcinoma, mainly its regional and metastatic stage, as an adjuvant to surgical resection of the tumor. In the medical l...
متن کاملMitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
CONTEXT Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC). A correlation between mitotane concentrations and patient outcome has not been demonstrated in an adjuvant setting. OBJECTIVE To compare recurrence-free survival (RFS) in patients who reached and maintained mitotane concentrat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Clinical Endocrinology & Metabolism
سال: 2013
ISSN: 0021-972X,1945-7197
DOI: 10.1210/jc.2013-2281